LOGIN  |  REGISTER
Terns Pharmaceuticals
Chimerix

Natera to Participate in Upcoming Investor Conferences

September 01, 2023 | Last Trade: US$148.08 2.09 -1.39

AUSTIN, Texas / Sep 01, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences:

  • The Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11 at 4:55 p.m. ET in New York, NY
  • The Baird 2023 Global Healthcare Conference on Tuesday, Sept. 12 at 4:20 p.m. ET in New York, NY

A live webcast and audio archive of each event may be accessed through the investor relations section of the Natera website at investor.natera.com. Replays will be available shortly thereafter.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Recursion

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page